Page last updated: 2024-10-27

fenofibrate and Craniopharyngioma

fenofibrate has been researched along with Craniopharyngioma in 1 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Craniopharyngioma: A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)

Research Excerpts

ExcerptRelevanceReference
" Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)."7.81Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015)
" Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)."3.81Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kalina, MA1
Wilczek, M1
Kalina-Faska, B1
Skała-Zamorowska, E1
Mandera, M1
Małecka Tendera, E1

Other Studies

1 other study available for fenofibrate and Craniopharyngioma

ArticleYear
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
    Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:1-2

    Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi

2015